Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date.

[View article]

[View interview]

The Shares Magazine Investor Evening presentation from 17 July 2019 is now available. Click here to view.

To review further documents and presentations, please click here.

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

[View article]

To download click here

To download click here.

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

[View article]

To download click here.

To download click here.

To download click here